GLP2-T
BW2-T (Tirzepatide)
Available Vial Sizes: 5 mg, 10 mg, 20 mg, 30 mg , 40 mg, 60 mg and 120 mg in a 3 mL vial
Tirzepatide is a novel synthetic dual agonist peptide that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is widely studied for its potent effects on metabolic regulation, glucose homeostasis, appetite suppression, and body weight management in laboratory and preclinical models.
In research settings, tirzepatide has shown superior efficacy compared to single GLP-1 agonists by simultaneously enhancing insulin secretion (glucose-dependent), suppressing glucagon release, slowing gastric emptying, and significantly reducing food intake. These combined actions make it a powerful research tool for investigating obesity, type 2 diabetes, cardiovascular outcomes, and advanced metabolic disorders.
This compound is offered strictly for research use only (RUO)
No description available.
Additional information
| Dosage | 5mg, 10mg, 20mg, 40mg, 30mg, 60mg, 120mg |
|---|